Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH)

Massimiliano Spaliviero, Motoo Araki, Jay B. Page, Carson Wong

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction and Objective: We evaluate the safety and efficacy of catheter-free LBO laser PVP for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Methods: We prospectively evaluated our initial LBO laser PVP experience and the need for urethral catheterization. Results: Seventy consecutive patients were identified. 49 (70%) were discharged without (C-) and 21 (30%) were discharged with (C+) a urethral catheter. There were no significant differences in pre-operative parameters, including age (C-: 65 ± 10 vs. C+: 69 ± 9 years), AUASS (C-: 22 ± 6 vs. C+: 21 ± 6), Qmax (C-: 10 ± 4 vs. C+: 8 ± 3 ml/second), PVR (C-: 62 ± 105 vs. C+: 57 ± 82 ml) and prostate volume (C-: 65 ± 35 vs. C+: 86 ± 53 ml). There were no significant differences in laser time and energy usage. AUASS, Qmax and PVR values showed significant improvement within each group (P <0.05), but there were no significant differences between the two groups. All were outpatient procedures. 2/70 (2.9%) patients required catheter reinsertion in C+. The overall incidence of adverse events was low and did not differ between the two groups. Conclusions: Our experience suggests that catheter-free LBO laser PVP is safe and effective for the treatment of LUTS secondary to BPH.

Original languageEnglish
Pages (from-to)529-534
Number of pages6
JournalLasers in Surgery and Medicine
Volume40
Issue number8
DOIs
Publication statusPublished - Oct 2008
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Laser Therapy
Prostatectomy
Lower Urinary Tract Symptoms
Catheters
Urinary Catheterization
Urinary Catheters
Prostate
Lasers
Outpatients
Safety
Incidence
Therapeutics
lithium borate

Keywords

  • Benign prostatic hyperplasia
  • Catheter duration
  • KTP laser
  • LBO laser
  • Lower urinary tract symptoms
  • Outcomes

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). / Spaliviero, Massimiliano; Araki, Motoo; Page, Jay B.; Wong, Carson.

In: Lasers in Surgery and Medicine, Vol. 40, No. 8, 10.2008, p. 529-534.

Research output: Contribution to journalArticle

@article{9206c149aedc4c2686db484e456cf603,
title = "Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH)",
abstract = "Introduction and Objective: We evaluate the safety and efficacy of catheter-free LBO laser PVP for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Methods: We prospectively evaluated our initial LBO laser PVP experience and the need for urethral catheterization. Results: Seventy consecutive patients were identified. 49 (70{\%}) were discharged without (C-) and 21 (30{\%}) were discharged with (C+) a urethral catheter. There were no significant differences in pre-operative parameters, including age (C-: 65 ± 10 vs. C+: 69 ± 9 years), AUASS (C-: 22 ± 6 vs. C+: 21 ± 6), Qmax (C-: 10 ± 4 vs. C+: 8 ± 3 ml/second), PVR (C-: 62 ± 105 vs. C+: 57 ± 82 ml) and prostate volume (C-: 65 ± 35 vs. C+: 86 ± 53 ml). There were no significant differences in laser time and energy usage. AUASS, Qmax and PVR values showed significant improvement within each group (P <0.05), but there were no significant differences between the two groups. All were outpatient procedures. 2/70 (2.9{\%}) patients required catheter reinsertion in C+. The overall incidence of adverse events was low and did not differ between the two groups. Conclusions: Our experience suggests that catheter-free LBO laser PVP is safe and effective for the treatment of LUTS secondary to BPH.",
keywords = "Benign prostatic hyperplasia, Catheter duration, KTP laser, LBO laser, Lower urinary tract symptoms, Outcomes",
author = "Massimiliano Spaliviero and Motoo Araki and Page, {Jay B.} and Carson Wong",
year = "2008",
month = "10",
doi = "10.1002/lsm.20678",
language = "English",
volume = "40",
pages = "529--534",
journal = "Lasers in Surgery and Medicine",
issn = "0196-8092",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH)

AU - Spaliviero, Massimiliano

AU - Araki, Motoo

AU - Page, Jay B.

AU - Wong, Carson

PY - 2008/10

Y1 - 2008/10

N2 - Introduction and Objective: We evaluate the safety and efficacy of catheter-free LBO laser PVP for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Methods: We prospectively evaluated our initial LBO laser PVP experience and the need for urethral catheterization. Results: Seventy consecutive patients were identified. 49 (70%) were discharged without (C-) and 21 (30%) were discharged with (C+) a urethral catheter. There were no significant differences in pre-operative parameters, including age (C-: 65 ± 10 vs. C+: 69 ± 9 years), AUASS (C-: 22 ± 6 vs. C+: 21 ± 6), Qmax (C-: 10 ± 4 vs. C+: 8 ± 3 ml/second), PVR (C-: 62 ± 105 vs. C+: 57 ± 82 ml) and prostate volume (C-: 65 ± 35 vs. C+: 86 ± 53 ml). There were no significant differences in laser time and energy usage. AUASS, Qmax and PVR values showed significant improvement within each group (P <0.05), but there were no significant differences between the two groups. All were outpatient procedures. 2/70 (2.9%) patients required catheter reinsertion in C+. The overall incidence of adverse events was low and did not differ between the two groups. Conclusions: Our experience suggests that catheter-free LBO laser PVP is safe and effective for the treatment of LUTS secondary to BPH.

AB - Introduction and Objective: We evaluate the safety and efficacy of catheter-free LBO laser PVP for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Methods: We prospectively evaluated our initial LBO laser PVP experience and the need for urethral catheterization. Results: Seventy consecutive patients were identified. 49 (70%) were discharged without (C-) and 21 (30%) were discharged with (C+) a urethral catheter. There were no significant differences in pre-operative parameters, including age (C-: 65 ± 10 vs. C+: 69 ± 9 years), AUASS (C-: 22 ± 6 vs. C+: 21 ± 6), Qmax (C-: 10 ± 4 vs. C+: 8 ± 3 ml/second), PVR (C-: 62 ± 105 vs. C+: 57 ± 82 ml) and prostate volume (C-: 65 ± 35 vs. C+: 86 ± 53 ml). There were no significant differences in laser time and energy usage. AUASS, Qmax and PVR values showed significant improvement within each group (P <0.05), but there were no significant differences between the two groups. All were outpatient procedures. 2/70 (2.9%) patients required catheter reinsertion in C+. The overall incidence of adverse events was low and did not differ between the two groups. Conclusions: Our experience suggests that catheter-free LBO laser PVP is safe and effective for the treatment of LUTS secondary to BPH.

KW - Benign prostatic hyperplasia

KW - Catheter duration

KW - KTP laser

KW - LBO laser

KW - Lower urinary tract symptoms

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=53249144149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249144149&partnerID=8YFLogxK

U2 - 10.1002/lsm.20678

DO - 10.1002/lsm.20678

M3 - Article

VL - 40

SP - 529

EP - 534

JO - Lasers in Surgery and Medicine

JF - Lasers in Surgery and Medicine

SN - 0196-8092

IS - 8

ER -